Clinical genitourinary cancerHumansAntibodiesMonoclonalHumanizedMale
Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.
Prateek Jain, Syed Arsalan Ahmed Naqvi, Nikita Tripathi, Japneet K Oberoi, Muhammad Abdullah Humayun, Yousef Zakharia, Jacob J Orme, Adam Kase, Dan S Childs, Ruqin Chen, Irbaz B Riaz, Parminder Singh
Published: 202510.1016/j.clgc.2025.102453
Abstract
INTRODUCTION: Enfortumab vedotin plus pembrolizumab has emerged as a new standard of care for previously untreated patients with advanced urothelial carcinoma following the EV-302 trial. However, data on its efficacy and safety in routine clinical pr…
Preview only. Read the full abstract at the source